New drug cocktail aims to shrink breast tumors before surgery

NCT ID NCT07383818

Recruiting now Disease control Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial is testing whether combining trastuzumab rezetecan (a targeted drug) with toripalimab (an immunotherapy) before surgery can eliminate more tumor tissue in women with HR-positive, HER2-low breast cancer. About 111 participants will receive the drug combo for 24 weeks, then undergo surgery. The main goal is to see how many achieve a pathologic complete response (no cancer cells left in the breast).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trastuzumab rezetecan and toripalimab
What this could lead to: If successful, this combination could become a new pre-surgery treatment option for HR+/HER2-low breast cancer, potentially improving tumor clearance and long-term outcomes.
What could go wrong: This is an early Phase 2 trial with only 111 participants, so results may not apply to all patients. The combination may cause side effects, and it is not yet known if it improves survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HR POSITIVE/HER2 LOW BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HR POSITIVE/HER2 LOW BREAST CANCER

Contacts and locations

Locations

Harbin Medical University Cancer Hospital
RECRUITING

Harbin, China
The First Affiliated Hospital of Anhui Medical University
RECRUITING

Hefei, China
The Second Affiliated Hospital of Xi'an Jiaotong University
RECRUITING

Xi'an, China
The Second Affiliated Hospital of Xi'an Jiaotong University
RECRUITING

Zhengzhou, China
Zhongshan Hospital, Fudan University
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.